PIMECROLIMUS
Clinical safety rating: safe
Animal studies have demonstrated safety
Pimecrolimus is a calcineurin inhibitor that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin-dependent T-cell activation, thereby suppressing pro-inflammatory cytokine production (e.g., IL-2, IFN-γ) and mast cell degranulation.
| Metabolism | Primarily metabolized via hepatic cytochrome P450 3A4 (CYP3A4) to O-demethylated metabolites; also undergoes further hydroxylation and glucuronidation. |
| Excretion | Primarily fecal (78.4% of dose) via biliary excretion; renal elimination accounts for <1% of unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 65 hours (range 22–115 hours) in adult atopic dermatitis patients, reflecting slow systemic clearance. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Approximately 1.3 L/kg (range 0.6–2.1 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is very low (<0.5% of applied dose) based on blood concentration measurements. |
| Onset of Action | Topical: Improvement noted within 1 week of twice-daily application; measurable reduction in pruritus and erythema often seen by day 3–5. |
| Duration of Action | Topical: Duration of effect persists for the treatment period; clinical improvement sustained with continued use. Upon discontinuation, symptoms may recur within days to weeks. |
Topical: Apply a thin layer of 1% cream to affected areas twice daily. Maximum daily dose: not established; usual amount is pea-sized per application. Not for continuous long-term use; intermittent use only.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal (<2.5%). |
| Liver impairment | No formal studies in hepatic impairment; based on minimal systemic absorption, no adjustment is likely required, but use caution in severe hepatic impairment due to theoretical risk of increased exposure. |
| Pediatric use | Children ≥2 years: Apply a thin layer of 1% cream to affected areas twice daily; maximum application area: <20% body surface area. Avoid use in children <2 years due to risk of systemic effects (insufficient data). |
| Geriatric use | No specific dose adjustment; use lowest effective amount due to potential for increased skin sensitivity and renal function decline with age. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions May increase risk of skin malignancies and lymphomas.
| Breastfeeding | It is not known whether pimecrolimus is excreted in human milk. Systemic absorption after topical application is minimal (<2.5 ng/mL), suggesting negligible transfer. However, due to potential for serious adverse reactions in nursing infants, caution should be exercised. M/P ratio is not available. Breastfeeding is generally considered acceptable with cautious use. |
| Teratogenic Risk | Pimecrolimus is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses 35 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: theoretical risk due to systemic absorption; avoid if possible. Second and third trimesters: limited data; risk of fetal harm cannot be excluded. |
■ FDA Black Box Warning
Long-term safety of topical calcineurin inhibitors has not been established; rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported; avoid continuous long-term use; limit use to indicated short-term and intermittent treatment.
| Common Effects | Burning |
| Serious Effects |
History of hypersensitivity to pimecrolimus or any component of the formulation; Netherton syndrome; generalized erythroderma; active viral, bacterial, or fungal skin infections at application site.
| Precautions | Increased risk of infections (e.g., varicella zoster, herpes simplex); avoid use on active infections; possible lymphadenopathy; photosensitivity (avoid UV exposure); monitor for skin atrophy; not recommended in children <2 years; use during pregnancy only if clearly needed. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of systemic infection or local skin reactions in the mother. Fetal monitoring not routinely required; however, if used extensively over large body surface areas, consider monitoring for potential adrenal suppression or immunosuppression in the neonate. |
| Fertility Effects | No specific human studies on fertility. Animal studies at high oral doses showed no impairment of fertility. Topical application is unlikely to affect fertility due to minimal systemic absorption. |